AUTL
Price
$1.28
Change
-$0.08 (-5.88%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
361.95M
117 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$11.18
Change
-$0.31 (-2.70%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
2.45B
116 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AUTL vs OCUL

Header iconAUTL vs OCUL Comparison
Open Charts AUTL vs OCULBanner chart's image
Autolus Therapeutics
Price$1.28
Change-$0.08 (-5.88%)
Volume$31.49K
Capitalization361.95M
Ocular Therapeutix
Price$11.18
Change-$0.31 (-2.70%)
Volume$47.12K
Capitalization2.45B
AUTL vs OCUL Comparison Chart in %
AUTL
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AUTL vs. OCUL commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (AUTL: $1.36 vs. OCUL: $11.49)
Brand notoriety: AUTL and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 155% vs. OCUL: 65%
Market capitalization -- AUTL: $339.33M vs. OCUL: $2.38B
AUTL [@Biotechnology] is valued at $339.33M. OCUL’s [@Biotechnology] market capitalization is $2.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, both AUTL and OCUL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 2 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • AUTL’s TA Score: 2 bullish, 6 bearish.
  • OCUL’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than AUTL.

Price Growth

AUTL (@Biotechnology) experienced а -1.81% price change this week, while OCUL (@Biotechnology) price change was +6.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

AUTL is expected to report earnings on Mar 10, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.45B) has a higher market cap than AUTL($362M). OCUL YTD gains are higher at: 34.543 vs. AUTL (-42.128). OCUL has higher annual earnings (EBITDA): -200.5M vs. AUTL (-232.19M). AUTL has more cash in the bank: 454M vs. OCUL (391M). AUTL has less debt than OCUL: AUTL (64.5M) vs OCUL (76.9M). OCUL has higher revenues than AUTL: OCUL (56.7M) vs AUTL (29.9M).
AUTLOCULAUTL / OCUL
Capitalization362M2.45B15%
EBITDA-232.19M-200.5M116%
Gain YTD-42.12834.543-122%
P/E RatioN/AN/A-
Revenue29.9M56.7M53%
Total Cash454M391M116%
Total Debt64.5M76.9M84%
FUNDAMENTALS RATINGS
AUTL vs OCUL: Fundamental Ratings
AUTL
OCUL
OUTLOOK RATING
1..100
5969
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
51
Fair valued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6450
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for OCUL (51) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew somewhat faster than OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (94) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as AUTL (97) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as AUTL (64) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLOCUL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
83%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMUBX26.390.22
+0.84%
MFS Utilities B
IPFPX57.380.13
+0.23%
Poplar Forest Partners Institutional
MVTIX11.35N/A
N/A
Transamerica Mid Cap Value Opps I
RMOCX18.25-0.02
-0.11%
Victory RS Mid Cap Growth C
LGRRX30.19-0.16
-0.53%
Loomis Sayles Growth A

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-9.33%
CRSP - AUTL
44%
Loosely correlated
-5.47%
IMTX - AUTL
43%
Loosely correlated
+16.10%
IPSC - AUTL
43%
Loosely correlated
N/A
BCYC - AUTL
43%
Loosely correlated
-3.95%
OCUL - AUTL
42%
Loosely correlated
+2.41%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+2.41%
IDYA - OCUL
57%
Loosely correlated
-0.19%
EYPT - OCUL
55%
Loosely correlated
+2.96%
DNLI - OCUL
55%
Loosely correlated
-0.34%
ERAS - OCUL
54%
Loosely correlated
+12.29%
RVMD - OCUL
53%
Loosely correlated
+2.73%
More